Prakhar Agrawal
Stock Analyst at Cantor Fitzgerald
(2.84)
# 2,018
Out of 5,182 analysts
53
Total ratings
42.55%
Success rate
9.78%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Prakhar Agrawal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| STTK Shattuck Labs | Initiates: Overweight | n/a | $7.80 | - | 1 | Apr 27, 2026 | |
| MANE Veradermics | Initiates: Overweight | n/a | $106.17 | - | 1 | Mar 2, 2026 | |
| EVMN Evommune | Initiates: Overweight | n/a | $25.06 | - | 1 | Dec 1, 2025 | |
| MDGL Madrigal Pharmaceuticals | Upgrades: Overweight | n/a | $524.00 | - | 5 | Nov 5, 2025 | |
| ATYR aTyr Pharma | Downgrades: Neutral | n/a | $0.80 | - | 2 | Sep 15, 2025 | |
| AVTX Avalo Therapeutics | Initiates: Overweight | n/a | $14.85 | - | 1 | Aug 15, 2025 | |
| GPCR Structure Therapeutics | Reiterates: Overweight | $65 | $47.04 | +38.18% | 13 | Jun 23, 2025 | |
| ORIC ORIC Pharmaceuticals | Reiterates: Overweight | n/a | $10.44 | - | 7 | May 6, 2025 | |
| TVTX Travere Therapeutics | Reiterates: Overweight | n/a | $41.64 | - | 3 | Apr 23, 2025 | |
| ACRS Aclaris Therapeutics | Reiterates: Overweight | n/a | $4.27 | - | 1 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $11.32 | - | 3 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $10 | $4.51 | +121.73% | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $17.03 | - | 10 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $24 | $35.46 | -32.32% | 2 | Apr 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $450 | $2.70 | +16,566.67% | 1 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $14 | $2.16 | +548.15% | 1 | Mar 3, 2021 |
Shattuck Labs
Apr 27, 2026
Initiates: Overweight
Price Target: n/a
Current: $7.80
Upside: -
Veradermics
Mar 2, 2026
Initiates: Overweight
Price Target: n/a
Current: $106.17
Upside: -
Evommune
Dec 1, 2025
Initiates: Overweight
Price Target: n/a
Current: $25.06
Upside: -
Madrigal Pharmaceuticals
Nov 5, 2025
Upgrades: Overweight
Price Target: n/a
Current: $524.00
Upside: -
aTyr Pharma
Sep 15, 2025
Downgrades: Neutral
Price Target: n/a
Current: $0.80
Upside: -
Avalo Therapeutics
Aug 15, 2025
Initiates: Overweight
Price Target: n/a
Current: $14.85
Upside: -
Structure Therapeutics
Jun 23, 2025
Reiterates: Overweight
Price Target: $65
Current: $47.04
Upside: +38.18%
ORIC Pharmaceuticals
May 6, 2025
Reiterates: Overweight
Price Target: n/a
Current: $10.44
Upside: -
Travere Therapeutics
Apr 23, 2025
Reiterates: Overweight
Price Target: n/a
Current: $41.64
Upside: -
Aclaris Therapeutics
Mar 18, 2025
Reiterates: Overweight
Price Target: n/a
Current: $4.27
Upside: -
Jan 21, 2025
Downgrades: Neutral
Price Target: n/a
Current: $11.32
Upside: -
Dec 17, 2024
Initiates: Overweight
Price Target: $10
Current: $4.51
Upside: +121.73%
Sep 23, 2024
Reiterates: Overweight
Price Target: n/a
Current: $17.03
Upside: -
Apr 17, 2023
Reiterates: Overweight
Price Target: $24
Current: $35.46
Upside: -32.32%
Jul 15, 2022
Assumes: Overweight
Price Target: $450
Current: $2.70
Upside: +16,566.67%
Mar 3, 2021
Initiates: Buy
Price Target: $14
Current: $2.16
Upside: +548.15%